stockrowBristol Myers Squibb Company (BMY) vs Novo Nordisk A/S (NVO)
- Bristol Myers Squibb Company BMY 62.12 −1.60%
- Novo Nordisk A/S NVO 40.23 −0.17%
Bristol Myers Squibb Company and Novo Nordisk A/S are both Drug Manufacturers General companies. Bristol Myers Squibb Company and Novo Nordisk A/S are of similar size ($134.8B and $129.0B). Novo Nordisk A/S trades at the lower P/E: 10.1× against 13.7×. Novo Nordisk A/S grew revenue faster over the last twelve months: 11.1% against 4.16%. Novo Nordisk A/S has the higher net margin (34.1% vs 18.5%) and the higher return on invested capital (29.6% vs 13.2%). Both pay a dividend; Novo Nordisk A/S yields more (4.46% vs 4.06%). Across the 23 metrics below, Novo Nordisk A/S leads on 16 and Bristol Myers Squibb Company on 7.
Valuation
Profitability
| Metric | BMY | NVO | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 69.24% | 80.89% | 73.01% |
| Operating margin | 22.65% | 42.66% | 18.34% |
| Net margin | 18.47% | 34.09% | 7.31% |
| Free cash flow margin | 18.56% | 13.25% | 18.56% |
| Return on equity | 44.01% | 58.84% | 5.80% |
| Return on assets | 9.96% | 20.52% | 2.28% |
| Return on invested capital | 13.19% | 29.63% | 6.26% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack